| Literature DB >> 17982189 |
Toshihiko Mizuta1, Iwata Ozaki.
Abstract
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17982189 DOI: CliCa071116931699
Source DB: PubMed Journal: Clin Calcium ISSN: 0917-5857